Registry update — unassessed
Characterization of mTOR Inhibitor Pharmacokinetics and Pharmacodynamics in Older Adults .
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jun 25, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Historical research backfill
What it does not prove
- This study does not demonstrate whether rapamycin actually slows aging or prevents chronic disease in older adults—it only characterizes how the drug behaves in this population. No clinical efficacy endpoints or health outcomes were reported. The abstract does not describe what was actually found, only what the study was designed to do, so no substantive results can be extracted.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Texas Southwestern Medical Center
- Published
- Jun 25, 2026
Sources
Primary source
- University of Texas Southwestern Medical Center ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes, preventing chronic disease and prolonging healthy lifespan, a major challenge in developing clinical trials to establish the clinical efficacy of mTOR inhibitors is the absence of pharmacokinetics (PK) and pharmacodynamics (PD) data in older adults. The proposed study will provide the foundation for future clinical trials assessing the role of mTOR inhibitors on aging related indications
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.